Oxford Finance announced that it closed a $17 million senior secured term loan with Entellus Medical.

Proceeds of the loan are being used to support the company’s ongoing commercialization of its therapeutic solutions for healthcare providers and their patients that suffer from sinusitis.

“Oxford is very pleased to provide Entellus Medical capital to market its innovative technologies,” said Christopher A. Herr, managing director for Oxford Finance.

“Entellus Medical’s high quality and minimally invasive therapeutic solutions greatly improve the procedure for treating sinusitis.”

“These funds allow Entellus to expand its efforts to bring highly efficacious and cost-saving sinusitis treatments to patients who can be treated in the convenience of the doctor’s office,” said Brian Farley, president and chief executive officer of Entellus.

“In doing so, doctors reduce the cost of treatment compared to conventional sinus surgery, while providing patients a treatment alternative with lower co-pays and very fast recovery.”